LIPO has a new catalyst

Reuters: "Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research"

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth
No FDA-approved therapy currently exists for OLP
Patient registry and OLP study information is now available

Triple Bottom holds the support.
Finaly breaks the minor order blocks with good volume

Once it clears 0.65$ resistance, 0,85$, 1.20$ and 1.50$ will be the target levels.